This trial is active, not recruiting.

Condition breast cancer
Treatments doxorubicin, cyclophosphamide, ixabepilone (ixempra), paclitaxel (taxol)
Phase phase 3
Sponsor SCRI Development Innovations, LLC
Collaborator Bristol-Myers Squibb
Start date January 2009
End date December 2015
Trial size 614 participants
Trial identifier NCT00789581, SCRI BRE 145, TITAN


This is a randomized, Phase III, open-label, multicenter study.

United States No locations recruiting
Other countries No locations recruiting

Study Design

Allocation randomized
Endpoint classification safety/efficacy study
Intervention model parallel assignment
Masking open label
Primary purpose treatment
(Active Comparator)
Doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2 administered for 4 cycles of 21 days each, followed by ixabepilone at 40 mg/m2 given for 4 cycles of 21 days each.
doxorubicin Adriamycin
Doxorubicin 60 mg/m2
cyclophosphamide Endoxan
Cyclophosphamide 600 mg/m2
ixabepilone (ixempra) Ixempra
Ixabepilone 40 mg/m2
(Active Comparator)
Doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2 administered for 4 cycles of 21 days each, followed by paclitaxel at 80 mg/m2 weekly for 12 weeks.
doxorubicin Adriamycin
Doxorubicin 60 mg/m2
cyclophosphamide Endoxan
Cyclophosphamide 600 mg/m2
paclitaxel (taxol) Taxol
Paclitaxel 80 mg/m2

Primary Outcomes

Disease Free Survival
time frame: 5.25 years

Secondary Outcomes

Overall Survival
time frame: 5.25 years
Number of treatment-emergent adverse events as a measure of safety.
time frame: evry 21 days for duration of treatment

Eligibility Criteria

Female participants at least 18 years old.

Inclusion Criteria: 1. Female patients greater than or equal to18 years of age. 2. Histologically confirmed invasive unilateral breast cancer (regardless of histology). 3. Early-stage breast cancer, defined as: - Node-positive disease: >0.2-mm metastasis in at least one lymph node (pN1mipN2b)OR - Node-negative, with primary tumor >1.0 cm (T1c-T3). 4. Definitive loco-regional surgery must have been completed as specified below: - Patients must have undergone either breast conservation surgery (i.e., lumpectomy) or total mastectomy. - Surgical margins of the resected section must be histologically free of invasive adenocarcinoma and ductal carcinoma in situ. - Surgical margins involved with lobular carcinoma in situ (LCIS) will not be considered as a positive margin; therefore, such patients will be eligible for this study without additional resection. - Patients must have completed axillary lymph node sampling for the pathologic evaluation of axillary lymph nodes as specified below: Sentinel node biopsy and/or either lymph node sampling procedure or axillary dissection. 5. Multicentric and multifocal invasive breast cancer is eligible if loco-regional surgery has been completed as described above. 6. Patients with synchronous bilateral cancers are eligible only if: - All cancers are of triple-negative phenotype, defined as ER-, PR-, HER2-. - Eligibility based on the highest stage grouping. 7. HER2 negative tumors. HER2 negativity must be confirmed by one of the following: - FISH-negative (FISH ratio <2.2), or - IHC 0-1+, or - IHC 2-3+ AND FISH-negative (FISH ratio <2.2). 8. Estrogen receptor negative (<10% staining by IHC for estrogen receptor). 9. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1. 10. Patient must be <= 84 days from having completed definitive primary breast surgery (either lumpectomy or mastectomy). 11. MammoSite brachytherapy radiation is acceptable if it is performed immediately following surgery and prior to chemotherapy. It is recommended that chemotherapy be started no earlier than 2 weeks following the removal of the MammoSite balloon catheter. 12. Adequate hematologic function, defined by: - Absolute neutrophil count (ANC) >1500/mm3 - Platelet count >=100,000/mm3 - Hemoglobin >9 g/dL 13. Adequate liver function, defined by: - AST and ALT <=2.5 x the upper limit of normal (ULN) - Total bilirubin <=1.5 x ULN (unless the patient has grade 1 bilirubin elevation due to Gilbert's disease or a similar syndrome involving slow conjugation of bilirubin). 14. Adequate renal function, defined by: - Serum creatinine <=1.5 x ULN 15. Complete staging work-up <=12 weeks prior to initiation of study treatment with computed tomography (CT) scans of the chest and abdomen/pelvis (abdomen/pelvis preferred; abdomen accepted), and either a positron emission tomography (PET) scan or a bone scan. 16. Adequate cardiac function, defined by a left ventricular ejection fraction (LVEF) value of >50% (or normal per institutional guidelines) by MUGA scan or echocardiogram (ECHO). 17. Adequate recovery from recent surgery. At least 1 week must have elapsed from the time of a minor surgery (i.e., sentinel node biopsy, port-acath (placement); at least 3 weeks must have elapsed from the time of a major surgery (i.e., lumpectomy, partial or total mastectomy, axillary lymph node dissection, breast reconstruction procedure). 18. Patients with previous history of invasive cancers (including breast cancer) are eligible if definitive treatment was completed more than 5 years prior to initiating current study treatment, and there is no evidence of recurrent disease. 19. Women of childbearing potential must have a negative serum or urine pregnancy test performed within 7 days prior to start of treatment. If a woman becomes pregnant or suspects she is pregnant while participating in this study, she must agree to inform her treating physician immediately. 20. Patient must be accessible for treatment and follow-up. 21. Women of childbearing potential must agree to use an acceptable method of birth control to avoid pregnancy for the duration of study treatment, and for 3 months thereafter. 22. All patients must be able to understand the investigational nature of the study and give written informed consent prior to study entry. Exclusion Criteria: 1. Women who are pregnant or breastfeeding. 2. History of previous diagnosis of invasive breast cancer (unless treated >5 years previously with no recurrence). History of previously treated ductal carcinoma in situ (DCIS) is acceptable. 3. Any evidence or suspicion of metastatic disease other than ipsilateral axillary lymph nodes. 4. Any tumor >=T4 (cutaneous invasion, deep adherence, inflammatory breast cancer). 5. Previous anthracycline chemotherapy. 6. Concurrent use of CYP3A4 inhibitors from 72 hours prior to initiation of study treatment until the end of treatment with ixabepilone. 7. Previous treatment for this breast cancer (including neoadjuvant chemotherapy). 8. Previous cancer (with the exception of non-melanoma skin cancer or cervical carcinoma in situ) in the past 5 years (including invasive contralateral breast cancer). 9. Peripheral neuropathy of > grade 1 per NCI CTCAE v3.0. 10. Cardiac disease, including: congestive heart failure (CHF) > Class II per New York Heart Association (NYHA) classification; unstable angina (anginal symptoms at rest) or new-onset angina (i.e., began within the last 3 months), or myocardial infarction within the past 6 months; symptomatic CHF, unstable angina pectoris, cardiac arrhythmia, or cardiac ventricular arrhythmias requiring anti-arrhythmic therapy. 11. History of hypersensitivity to CremophorEL (polyoxyethylated castor oil) or a drug formulated in CremophorEL such as paclitaxel. 12. Use of any investigational agent within 30 days of administration of the first dose of study drug. 13. Patients may not receive any other investigational or anti-cancer treatments while participating in this study. 14. Concurrent severe, uncontrolled infection or intercurrent illness including, but not limited to, ongoing or active infection, or psychiatric illness/social situations that would limit compliance with study requirements. 15. Mental condition that would prevent patient comprehension of the nature of, and risk associated with, the study. 16. Inability to comply with study and/or follow-up procedures.

Additional Information

Official title Phase III Study of Doxorubicin/Cyclophosphamide (AC) Followed by Ixabepilone vs. AC Followed by Paclitaxel in Patients With Triple-Negative Early-Stage Breast Cancer
Description Patients will be randomized in a 1:1 ratio to receive one of two different treatment arms. Patients in treatment arm 1 will receive AC followed by ixabepilone. Patients in treatment arm 2 will receive AC followed by weekly paclitaxel.
Trial information was received from ClinicalTrials.gov and was last updated in June 2016.
Information provided to ClinicalTrials.gov by SCRI Development Innovations, LLC.